These are the most common drivers of clinical NSCLC, with approximate gene alteration rates of 20% for LKB1, 36% for KRAS and 46% for TP53 in adenocarcinomas (ACs) 17, 18. This evidence concerns the gene KRAS and non-small cell lung carcinoma.